Abstract
The advanced glycoxidation end products (AGEs) and lipoxidation end products (ALEs) contribute to the development of diabetic complications and of other pathologies. The review discusses the possibilities of counteracting the formation and stimulating the degradation of these species by pharmaceuticals and natural compounds. The review discusses inhibitors of ALE and AGE formation, cross-link breakers, ALE/AGE elimination by enzymes and proteolytic systems, receptors for advanced glycation end products (RAGEs) and blockade of the ligand-RAGE axis.
MeSH terms
-
Antioxidants / metabolism*
-
Antioxidants / pharmacology
-
Cross-Linking Reagents / metabolism
-
Cross-Linking Reagents / pharmacology
-
Diabetes Complications / metabolism
-
Diabetes Mellitus / drug therapy*
-
Diabetes Mellitus / metabolism
-
Diabetes Mellitus / physiopathology
-
Glycation End Products, Advanced / antagonists & inhibitors
-
Glycation End Products, Advanced / metabolism*
-
Humans
-
Lipid Peroxidation*
-
Proteasome Endopeptidase Complex / drug effects
-
Proteasome Endopeptidase Complex / metabolism
-
Proteolysis / drug effects
-
Receptor for Advanced Glycation End Products / metabolism
Substances
-
Antioxidants
-
Cross-Linking Reagents
-
Glycation End Products, Advanced
-
Receptor for Advanced Glycation End Products
-
Proteasome Endopeptidase Complex